These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 7013002)

  • 1. Comparative studies of intermittent and continuous administration of aminoglycosides in the treatment of bronchopulmonary infections due to gram-negative bacteria.
    Klastersky J; Thys JP; Mombelli G
    Rev Infect Dis; 1981; 3(1):74-83. PubMed ID: 7013002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on good use of injectable aminoglycosides, gentamycin, tobramycin, netilmycin, amikacin. Pharmacological properties, indications, dosage, and mode of administration, treatment monitoring.
    Agence française de sécurité sanitaire des produits de santé
    Med Mal Infect; 2012 Jul; 42(7):301-8. PubMed ID: 22770656
    [No Abstract]   [Full Text] [Related]  

  • 3. The aminoglycosides. Streptomycin, kanamycin, gentamicin, tobramycin, amikacin, netilmicin, sisomicin.
    Edson RS; Keys TF
    Mayo Clin Proc; 1983 Feb; 58(2):99-102. PubMed ID: 6823164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-Pseudomonas activity in bronchial secretions of patients receiving amikacin or tobramycin as a continuous infusion.
    Mombelli G; Coppens L; Thys JP; Klastersky J
    Antimicrob Agents Chemother; 1981 Jan; 19(1):72-5. PubMed ID: 7247362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal antibiotic therapy in bronchopulmonary infections.
    Neu HC
    Infection; 1980; Suppl 1():62-9. PubMed ID: 7399717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The aminoglycosides: streptomycin, kanamycin, gentamicin, tobramycin, amikacin, netilmicin, and sisomicin.
    Edson RS; Terrell CL
    Mayo Clin Proc; 1987 Oct; 62(10):916-20. PubMed ID: 3657309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenging conventional aminoglycoside dosing regimens. The value of experimental models.
    Kapusnik JE; Sande MA
    Am J Med; 1986 Jun; 80(6B):179-81. PubMed ID: 3089001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel approaches for the use of aminoglycosides: the value of experimental models.
    Kapusnik JE; Sande MA
    J Antimicrob Chemother; 1986 Mar; 17 Suppl A():7-10. PubMed ID: 3710965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The role of aminoglycoside--modifying enzymes in resistance of Gram-negative rods].
    Jakoniuk P; Wieczorek P; Sacha PT; Zalewska M; Leszczyńska K
    Med Dosw Mikrobiol; 2006; 58(4):363-70. PubMed ID: 17642314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surveillance of aminoglycoside resistance. European data.
    Van Landuyt HW; Boelaert J; Glibert B; Gordts B; Verbruggen AM
    Am J Med; 1986 Jun; 80(6B):76-81. PubMed ID: 3089007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Susceptibility of aerobic gram-negative bacilli to aminoglycosides. Effects of 45 months of amikacin as first-line aminoglycoside therapy.
    Saavedra S; Vera D; Ramírez-Ronda CH
    Am J Med; 1986 Jun; 80(6B):65-70. PubMed ID: 3014877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo effect of aminoglycoside on Pseudomonas aeruginosa in experiment.
    Uxová M; Vrbová E; Výmola F
    Czech Med; 1986; 9(4):206-9. PubMed ID: 3102186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parenteral aminoglycoside therapy. Selection, administration and monitoring.
    Kumana CR; Yuen KY
    Drugs; 1994 Jun; 47(6):902-13. PubMed ID: 7521830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incorporation, release and in-vitro antibacterial activity of liposomal aminoglycosides against Pseudomonas aeruginosa.
    Omri A; Ravaoarinoro M; Poisson M
    J Antimicrob Chemother; 1995 Oct; 36(4):631-9. PubMed ID: 8591937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aminoglycoside antibiotics in infectious diseases. An overview.
    Siegenthaler WE; Bonetti A; Luthy R
    Am J Med; 1986 Jun; 80(6B):2-14. PubMed ID: 3524216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Aminoglycoside resistance of enterobacteria isolated from urinary infections in surgical departments].
    Muntean D; Licker M; Berceanu-Văduva D; Crăciunescu M; Hogea E; Popa M; Adămut M; Rădulescu M; Moldovan R
    Bacteriol Virusol Parazitol Epidemiol; 2008; 53(2):99-102. PubMed ID: 19856848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of aminoglycoside cycling in six tertiary intensive care units: prospective longitudinal interventional study.
    Francetić I; Kalenić S; Huić M; Mercep I; Makar-Ausperger K; Likić R; Erdeljić V; Tripković V; Simić P
    Croat Med J; 2008 Apr; 49(2):207-14. PubMed ID: 18461676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of aminoglycosides in surgical infections.
    Stone HH; Kolb LD; Geheber CE; Dawkins EJ
    Ann Surg; 1976 Jun; 183(6):660-6. PubMed ID: 973753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gentamicin, tobramycin, amikacin, and netilmicin levels in tears following intravenous administration.
    Woo FL; Johnson AP; Insler MS; George WJ; LaCorte WS
    Arch Ophthalmol; 1985 Feb; 103(2):216-8. PubMed ID: 3977692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of dosing strategy on kidney cortical accumulation of aminoglycosides in rats.
    Giuliano RA; Verpooten GA; De Broe ME
    Am J Kidney Dis; 1986 Nov; 8(5):297-303. PubMed ID: 3788968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.